Takeaway
- Pooled data from 3 randomised controlled trials confirmed the efficacy of tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis.
- Higher doses of tildrakizumab may improve efficacy in heavier patients.
Why this matters
- Pooling data allow for more robust assessment of subgroups vs individual trials.
Study design
- Analysis of pooled data of 2081 patients with plaque psoriasis from 3 randomised trials.
- Patients received tildrakizumab 100/200 mg or placebo/etanercept.
- Primary endpoint: proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 16.
- Funding: Merck & Co., Inc., Kenilworth, NJ, USA.
Key results
- At week 12, proportions of PASI 75 responders were significantly higher with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs placebo (5.6%; P<.0001).
- Proportion of patients achieving PASI 90, PASI 100 and Physician’s Global Assessment (PGA) ‘clear’ or ‘minimal’ were significantly higher with tildrakizumab vs placebo (P<.0001).
- Responses increased from week 12 to 28.
- Week 12 PASI and PGA responses to tildrakizumab vs placebo were numerically greater in patients with lower vs higher bodyweight.
- Responses for patients with higher bodyweight were generally better with tildrakizumab 200 mg than with tildrakizumab 100 mg vs placebo or etanercept.
- Week 12 PASI 75 responses vs placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics.
Limitations
- Long-term data not available.
References
References
